Karyopharm Therapeutics
KPTI
171 hedge funds and large institutions have $637M invested in Karyopharm Therapeutics in 2021 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 57 increasing their positions, 57 reducing their positions, and 24 closing their positions.
17% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 24
2% more funds holding
Funds holding: 168 → 171 (+3)
0% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 57
0.41% less ownership
Funds ownership: 5.78% → 5.37% (-0.41%)
34% less call options, than puts
Call options by funds: $2.61M | Put options by funds: $3.95M
36% less capital invested
Capital invested by funds: $988M → $637M (-$351M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$20.4M |
| 2 |
JGC
J. Goldman & Co
New York
|
+$15M |
| 3 |
Morgan Stanley
New York
|
+$13.4M |
| 4 |
CLOS
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
|
+$11.7M |
| 5 |
LOAMS
Lombard Odier Asset Management (Switzerland)
Petit-Lancy,
Switzerland
|
+$11.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$26.8M |
| 2 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$25M |
| 3 |
Millennium Management
New York
|
-$24.7M |
| 4 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$23.2M |
| 5 |
D.E. Shaw & Co
New York
|
-$19.2M |
KPTI Hedge Fund Activity: Q1 2021 in Review
171 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q1 2021, worth a combined $637M — down 36% from $988M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new KPTI positions and 24 closed out — a net gain of 4 holders — while 57 added to existing stakes and 57 trimmed.
The largest buyer was Two Sigma Investments, adding an estimated $20.4M. The largest seller was Frontier Capital Management, cutting an estimated $26.8M.
- 171 institutional investors held Karyopharm Therapeutics (KPTI) as of Q1 2021, up from 168 in Q4 2020.
- Funds reported $637M of Karyopharm Therapeutics stock for Q1 2021, down 36% quarter-over-quarter.
- 28 funds opened new Karyopharm Therapeutics positions in Q1 2021 and 24 closed out, a net change of +4 holders.
- The largest Karyopharm Therapeutics buyer in Q1 2021 was Two Sigma Investments, an estimated $20.4M added.
- The largest Karyopharm Therapeutics seller in Q1 2021 was Frontier Capital Management, an estimated $26.8M sold.
Based on aggregated 13F filings for Q1 2021.